These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38887198)

  • 21. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation.
    Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK
    Elife; 2024 Jul; 12():. PubMed ID: 38973593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
    Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
    J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vidofludimus inhibits porcine reproductive and respiratory syndrome virus infection by targeting dihydroorotate dehydrogenase.
    Yang Y; Gao Y; Zhang L; Liu X; Sun Y; Bai J; Jiang P
    Vet Res; 2023 Dec; 54(1):124. PubMed ID: 38124181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML.
    DeRatt LG; Zhang Z; Pietsch C; Cisar JS; Zhang X; Wang W; Tanner A; Matico R; Shaffer P; Jacoby E; Kazmi F; Shukla N; Bush TL; Patrick A; Philippar U; Attar R; Edwards JP; Kuduk SD
    J Med Chem; 2024 Jul; 67(13):11254-11272. PubMed ID: 38889244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
    Mei-Jiao G; Shi-Fang L; Yan-Yan C; Jun-Jun S; Yue-Feng S; Ting-Ting R; Yong-Guang Z; Hui-Yun C
    Biomed Pharmacother; 2019 Oct; 118():109305. PubMed ID: 31545264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
    Singh A; Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Original Chemical Series of Pyrimidine Biosynthesis Inhibitors That Boost the Antiviral Interferon Response.
    Lucas-Hourani M; Dauzonne D; Munier-Lehmann H; Khiar S; Nisole S; Dairou J; Helynck O; Afonso PV; Tangy F; Vidalain PO
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28807907
    [No Abstract]   [Full Text] [Related]  

  • 29. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
    Coelho AR; Oliveira PJ
    Eur J Clin Invest; 2020 Oct; 50(10):e13366. PubMed ID: 32735689
    [No Abstract]   [Full Text] [Related]  

  • 30. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis.
    Wang QY; Bushell S; Qing M; Xu HY; Bonavia A; Nunes S; Zhou J; Poh MK; Florez de Sessions P; Niyomrattanakit P; Dong H; Hoffmaster K; Goh A; Nilar S; Schul W; Jones S; Kramer L; Compton T; Shi PY
    J Virol; 2011 Jul; 85(13):6548-56. PubMed ID: 21507975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.
    Madak JT; Cuthbertson CR; Miyata Y; Tamura S; Petrunak EM; Stuckey JA; Han Y; He M; Sun D; Showalter HD; Neamati N
    J Med Chem; 2018 Jun; 61(12):5162-5186. PubMed ID: 29727569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of pyrimidine biosynthesis by targeting DHODH enzyme robustly inhibits rotavirus replication.
    Chen S; Ding S; Yin Y; Xu L; Li P; Peppelenbosch MP; Pan Q; Wang W
    Antiviral Res; 2019 Jul; 167():35-44. PubMed ID: 30974126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay.
    Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S
    Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.
    Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB
    Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
    Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
    Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
    Popova G; Ladds MJGW; Johansson L; Saleh A; Larsson J; Sandberg L; Sahlberg SH; Qian W; Gullberg H; Garg N; Gustavsson AL; Haraldsson M; Lane D; Yngve U; Lain S
    J Med Chem; 2020 Apr; 63(8):3915-3934. PubMed ID: 32212728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH.
    Abdullah I; Chee CF; Lee YK; Thunuguntla SSR; Satish Reddy K; Nellore K; Antony T; Verma J; Mun KW; Othman S; Subramanya H; Rahman NA
    Bioorg Med Chem; 2015 Aug; 23(15):4669-4680. PubMed ID: 26088338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydroorotate Dehydrogenase as a Target for the Development of Novel Helicobacter pylori-Specific Antimicrobials.
    Ohishi T; Inaoka DK; Kita K; Kawada M
    Chem Pharm Bull (Tokyo); 2018; 66(3):239-242. PubMed ID: 29491257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacokinetic drug-drug interaction study between rosuvastatin and emvododstat, a potent anti-SARS-CoV-2 (COVID-19) DHODH (dihydroorotate dehydrogenase) inhibitor.
    Morton TL; Laskin OL; Kaushik D; Lee L; Ma J; Kristensen A; O'Keefe K; Golden L; Klein M; Kong R
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01076. PubMed ID: 36938928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
    Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC
    Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.